Made Scientific to Manufacture Regenicin’s NovaDerm for FDA Orphan Drug Push
Event summary
- Made Scientific will manufacture Regenicin’s NovaDerm, an autologous cultured skin substitute, at its Princeton GMP facility.
- The partnership aims to advance NovaDerm toward FDA Orphan product approval.
- Made Scientific will support Regenicin’s IND submission and upcoming clinical trial.
- NovaDerm is designed for severe burns and chronic wounds, requiring less tissue harvesting.
The big picture
This partnership underscores the growing reliance on specialized CDMOs like Made Scientific to navigate the complexities of autologous cell therapy manufacturing. The collaboration also highlights the strategic importance of FDA Orphan Drug designation for regenerative medicine startups aiming to treat niche but high-impact conditions. With GC Corporation’s backing, Made Scientific is positioning itself as a key player in the cell therapy space, supporting innovative therapies like NovaDerm that could redefine wound care.
What we're watching
- Regulatory Milestones
- The pace at which Regenicin advances NovaDerm through IND submission and clinical trials will determine its FDA approval timeline.
- Manufacturing Scalability
- Whether Made Scientific can maintain consistency and traceability in producing patient-specific treatments like NovaDerm.
- Market Differentiation
- How NovaDerm’s reduced tissue harvesting and hospitalization time will position it against existing burn and wound treatments.
Related topics